Inventor
METZNER HUBERT
DE27 patents
⚠️ This page may combine multiple inventors who share the name “METZNER HUBERT”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CSL BEHRING GMBH
8 patentsUS7939632B2May 10, 2011
Proteolytically cleavable fusion proteins with high molar specific activity
CSL BEHRING GMBH40 citations92
US7351561B2Apr 1, 2008
Thrombin preparations and process for their production
CSL BEHRING GMBH28 citations92
US7550567B2Jun 23, 2009
Fibrinogen purification
CSL BEHRING GMBH21 citations89
US7939288B2May 10, 2011
Method for differentiating between factor XIII deficiency states and fibrinogen deficiency states by means of thrombelastographic techniques
CSL BEHRING GMBH7 citations79
US8012728B2Sep 6, 2011
Thrombin preparations and process for their production
CSL BEHRING GMBH2 citations62
US11554156B2Jan 17, 2023
Pharmaceutical formulations of C1 esterase inhibitor
CSL BEHRING GMBH0 citations53
US9511123B2Dec 6, 2016
Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII
CSL BEHRING GMBH0 citations51
US9393289B2Jul 19, 2016
Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII
CSL BEHRING GMBH0 citations40
CSL LTD
7 patentsUS9956269B2May 1, 2018
Method for improving the stability of purified factor VIII after reconstitution
CSL LTD12 citations91
US10537616B2Jan 21, 2020
Method for improving the stability of purified factor VIII after reconstitution
CSL LTD5 citations83
US9394353B2Jul 19, 2016
Method for improving the stability of purified factor VIII after reconstitution
CSL LTD9 citations83
US9878017B2Jan 30, 2018
Covalent complex of von Willebrand Factor and factor VIII, compositions, and uses relating thereto
CSL LTD4 citations73
US10881717B2Jan 5, 2021
Method for improving the stability of purified Factor VIII after reconstitution
CSL LTD3 citations72
US11510968B2Nov 29, 2022
Method for improving the stability of purified Factor VIII after reconstitution
CSL LTD0 citations61
US10238718B2Mar 26, 2019
Factor VIII formulation
CSL LTD0 citations44
AVENTIS BEHRING GMBH
4 patentsUS6204036B1Mar 20, 2001
Stable transglutaminase preparations and processes for their production
AVENTIS BEHRING GMBH26 citations91
US6447774B1Sep 10, 2002
Stabilized protein preparations for a tissue adhesive
AVENTIS BEHRING GMBH31 citations90
US6790410B2Sep 14, 2004
Use of a hydrogen peroxide plasma sterilization method for the mild sterilization of temperature-sensitive products
AVENTIS BEHRING GMBH17 citations80
US6207877B1Mar 27, 2001
Transgenic coagulation factor XIII defective animal and its use for testing wound healing and bleeding
AVENTIS BEHRING GMBH1 citations51
CSL Behring Lengnau AG
3 patentsUS10688157B2Jun 23, 2020
Truncated von Willebrand factor polypeptides for treating hemophilia
CSL Behring Lengnau AG2 citations72
US11479578B2Oct 25, 2022
Protein purification and virus inactivation with alkyl glycosides
CSL Behring Lengnau AG0 citations58
US11814421B2Nov 14, 2023
Truncated von Willebrand Factor polypeptides for treating hemophilia
CSL Behring Lengnau AG0 citations50